31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Novartis bets $2bn on biologics as Xolair patents fade

27 March 2026 The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market.

Europe

WIPR debuts Global In-House Elite 2026

26 March 2026 LSIPR sister title launches vetted list celebrating leading in-house counsel who demonstrate exceptional ability in managing their organisation's IP portfolio, legal team, and IP culture.

Biotechnology

mRNA litigation: Who’s winning, who’s filing, and what’s next

25 March 2026 As the world moves past the pandemic, a massive legal struggle over the future of mRNA technology is just hitting its stride. LSIPR visualises the litigation defining the next era.

More features

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Arnold & Porter adds tech litigator in San Francisco

To cite or not to cite: How can we avoid misuse of AI in court?

Emotional Perception: What next for patent holders?

Nine-partner litigation team leaves Winston & Strawn

Firm adds seven-lawyer team in second major merger

Rooted in rights: Lessons from plant patent infringement and invalidity cases

Final call: Who are the world’s best in-house counsel?

Copyright compliance in the life sciences industry

More on this story

Editor's picks

Editor's picks

More features